^
Association details:
| Biomarker: | MSLN positive |
|---|---|
| Cancer: | Solid Tumor |
| Drug Class: | T-lymphocyte cell therapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Safety and efficacy of chimeric antigen receptor T cells modified to target mesothelin and express PD-1 antibodies in patients with relapsed/refractory solid cancers in a phase I trial.
Published date:
05/13/2020
Excerpt:
10 patients with mesothelin positive relapsed/refractory solid cancers after failure to standard therapies were treated with aPD1-MSLN-CAR T cells...After aPD1-MSLN-mRNA-CAR T cells treatment, 2 patients (20%) achieved partial response (PR), 4 (40%) remained stable (SD), and the rest 4 (40%) patients developed disease progression (PD)….These findings lend support that the combination of modified CAR T cells targeting MSLN with PD1 inhibition for solid tumors is safe.
DOI:
10.1200/JCO.2020.38.15_suppl.3041
Trial ID:
